Amgen is helping to transform care delivery by focusing on precise solutions, while continuing to innovate to address areas of high unmet medical need. We’re doing this through the development and application of precision and personalized medicine, as well as digital health solutions.
To drive the next generation of precision medicine and personalized treatment approaches, Amgen applies expertise in R&D, drug discovery, human –“omics,” emerging technology and data analytics to expand our ability to address a number of the leading causes of death and disability.
Amgen is focused on the pursuit of therapies with large effects in serious diseases. Our investments in R&D are designed to generate the next generation of medicines that treat patients in a more precise, personalized way.
Our investments position us for long-term success through:
*This is a non-GAAP financial measure. 2015-2019 Amgen Inc. Full Year Financial Results.
Read more about our Research and Development activities in Europe
We’re making strategic technological decisions to position Amgen as the therapeutic leader of choice for patients and health systems throughout the entire patient journey. When we discover, develop, analyze and apply novel technologies in an integrated way, we have the potential to improve the impact of our medicines.
From remote patient monitoring to machine learning and predictive AI models, we’re applying our data analytics capabilities, science-based culture, and industry knowledge to develop more personalized solutions, with the goal of ushering in a long overdue healthcare transformation.
Our portfolio encompasses a significant number of projects that leverage data science and emerging digital health solutions to create a more connected, agile, personalized health ecosystem – with the goal of bringing providers and patients closer together.
Amgen is investing in more than 110 value-based partnerships in Europe across 21 countries including 36 in bone, 33 in cardiovascular, 31 in oncology and 7 in areas such as inflammation and nephrology.
1. Amgen 2019 Letter to Shareholders.